| Literature DB >> 22440017 |
María Ercibengoa1, Nerea Arostegi, José M Marimón, Marta Alonso, Emilio Pérez-Trallero.
Abstract
BACKGROUND: Pneumococcal nasopharyngeal carriage precedes invasive infection and is the source for dissemination of the disease. Differences in sampling methodology, isolation or identification techniques, as well as the period (pre -or post-vaccination) when the study was performed, can influence the reported rates of colonization and the distribution of serotypes carried.Entities:
Mesh:
Year: 2012 PMID: 22440017 PMCID: PMC3383471 DOI: 10.1186/1471-2334-12-69
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Number of samples investigated and percentage of positive colonization in three distinct time periods
| Children sampled on | Total samples | Nov 04/Feb 05 | May 05/Jun 05 | Nov 05/Dec 05 |
|---|---|---|---|---|
| 3 occasions (n = 25) | 60/75 (80%) | 22/25 (88%) | 20/25 (80%) | 18/25 (72%) |
| 2 occasions (n = 53) | 83/106 (78.3%) | 37/44 (84.1%) | 39/53 (73.6%) | 7/9 (77.8%) |
| 1 occasion (n = 27) | 18/27 (66.7%) | 2/3 (66.7%) | 3/4 (75%) | 13/20 (65%) |
| Total (n = 105) | 161/208 (77.4%) | 61/72 (84.7%) | 62/82 (75.6%) | 38/54 (70.4%) |
Streptococcus pneumoniae serotype distribution in nasopharyngeal samples of carriers collected on three distinct dates
| Time of sampling | Single or multiple carriage per sample | Total samples with this serotype | Serotyping method | Number of children colonized with this serotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serotypea | Winter 2004 | Spring 2005 | Winter 2005 | Single | With another one | With another two | With another three | Quellungb | Pneumotest Latexc | Multiplex PCR | ||
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 5 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | |||||
| 6A | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
| 13 | 2 | 2 | 9 | 4 | 15 | 15 | 14 | 15 | 14 | |||
| 6C | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | |||||
| 9N | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| 10A | 3 | 8 | 1 | 8 | 3 | 1 | 12 | 11 | 12 | 12 | 11 | |
| 10B | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| 11A | 12 | 2 | 2 | 8 | 3 | 1 | 14 | 11 | 11 | 14 | 13 | |
| 13 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||
| 6 | 6 | 8 | 3 | 1 | 12 | 6 | 6 | 12 | 12 | |||
| 15B | 8 | 10 | 3 | 14 | 5 | 2 | 21 | 20 | 20 | 21 | 20 | |
| 16F | 14 | 9 | 8 | 11 | 3 | 1 | 23 | 17 | 17 | 23 | 21 | |
| 19A | 9 | 12 | 20 | 30 | 9 | 2 | 41 | 41 | 41 | 41 | 36 | |
| 2 | 4 | 2 | 3 | 1 | 6 | 6 | 6 | 6 | 5 | |||
| 20 | 6 | 9 | 1 | 4 | 9 | 3 | 16 | 6 | 6 | 16 | 16 | |
| 21 | 7 | 6 | 9 | 3 | 1 | 13 | 13 | 13 | 13 | 13 | ||
| 22F | 2 | 1 | 2 | 1 | 3 | 1 | 1 | 3 | 3 | |||
| 23B | 6 | 3 | 1 | 7 | 2 | 1 | 10 | 10 | 10 | 10 | 9 | |
| 35F | 1 | 1 | 6 | 5 | 2 | 1 | 8 | 8 | 8 | 8 | 7 | |
| Total pneumococci serotyped | 87 | 79 | 39 | 102 | 70 | 29 | 4 | 205 | 175 | 175 | 205 | 191 |
| Non typeable isolates | 7 | 4 | 2 | 13 | 13 | 13 | 13 | 13 | 11 | |||
| Total pneumococci detected | 94 | 83 | 41 | 115 | 70 | 29 | 4 | 218 | 218 | |||
a Serotype: in bold, serotypes included in the seven-valent pneumococcal conjugate vaccine
b Quellung: serotype 6C-specific antiserum, factor 6 d, was not available at the moment of the study and serotype 6C was verified by using factor antiserum 6b
c Pneumotest-Latex kit: the kit used did not allow the identification at the serotype level, being identifications done at the serogroup level
Vaccination status and serotypes detected in three consecutive nasopharyngeal samples from 25 healthy children
| Children age (months)a | PCV7b doses | Winter 2004 | Spring 2005 | Winter 2005 |
|---|---|---|---|---|
| 5 | 0 | 19A | 19A | negative |
| 6 | 0 | 23B | negative | 23B |
| 6 | 0 | NTc | 21 | NT |
| 7 | 0 | negative | negative | negative |
| 7 | 0 | 6B + 21 | NT | negative |
| 10 | 0 | 19F + 21 | 10A | 19A |
| 11 | 0 | 16F | 19A | negative |
| 15 | 0 | 23B | 15B | 19A |
| 16 | 0 | 6B + 11A + 20 | 6B + 16F | 14 |
| 17 | 0 | negative | 23B | 14 |
| 4 | 1 | 19A | 35 | 14 + 19A + 35 |
| 5 | 1 | 11A + 15B | 16F + 19A | 35 |
| 6 | 1 | negative | 21 | 19A |
| 7 | 1 | 21 | 16F + 19F | 19A |
| 10 | 1 | NT | NT | 35 |
| 10 | 1 | 19A | negative | 19A |
| 9 | 2 | 6B + 19F + 21 | 10A + 19F | 19A |
| 16 | 2 | 16F | negative | negative |
| 7 | 3 | 21 | 16F + 19A | 14 |
| 9 | 3 | 6B + 21 | 19F | 19A |
| 10 | 3 | 6B + 21 | 14 | negative |
| 12 | 3 | negative | 16F + 20 | 19A |
| 12 | 3 | 16F + 35F | 15B | NT |
| 15 | 3 | NT | 11A + 19A | negative |
| 17 | 3 | 16F + 20 + 23B | 19A | 10A |
a Children age (months): when enrolling the study
b PCV7: 7-valent pneumococcal conjugate vaccine
c NT, non typeable but optochin, bile esculin and autolysin lytA gene positive